

FORM PTO-1390 (Modified)  
(REV 11-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

**TIENSE RAFF.28**

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

**09/700573**INTERNATIONAL APPLICATION NO.  
**PCT/EP99/03399**INTERNATIONAL FILING DATE  
**MAY 18, 1999**PRIORITY DATE CLAIMED  
**MAY 18, 1998**

TITLE OF INVENTION

**SYNERGISTIC COMPOSITION FOR USE IN THE TREATMENT OF CANCER**

APPLICANT(S) FOR DO/EO/US

**Henryk TAPER, Anne FRIPPIAT, Jan VAN LOO and Marcel ROBERFROID**

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

**Items 13 to 20 below concern document(s) or information included:**

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

**Prior Art Disclosure Statement (2 pgs)  
PTO-1449 (1 pg) with 2 references affixed thereto (cited in the International Search Report)  
Request Form PCT/RO/101 (4 pgs)**

U.S. APPLICATION NO. (UNKNOWN SEE 37 CFR)  
**09/700573**INTERNATIONAL APPLICATION NO.  
**PCT/EP99/03399**ATTORNEY'S DOCKET NUMBER  
**TIENSE RAFF.28**

21. The following fees are submitted:.

**BASIC NATIONAL FEE ( 37 CFR 1.492 (a) (1) - (5)) :**

- ☐ Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... **\$970.00**
- ☒ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... **\$840.00**
- ☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... **\$690.00**
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... **\$670.00**
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) ..... **\$96.00**

**ENTER APPROPRIATE BASIC FEE AMOUNT =****\$840.00**Surcharge of **\$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).**\$0.00**

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	20 - 20 =	0	x \$18.00
Independent claims	3 - 3 =	0	x \$78.00

**\$0.00****\$0.00**Multiple Dependent Claims (check if applicable). ☐**\$0.00****TOTAL OF ABOVE CALCULATIONS =****\$840.00**Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). ☐**\$0.00****SUBTOTAL =****\$840.00**Processing fee of **\$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).**\$0.00****TOTAL NATIONAL FEE =****\$840.00**Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☒**\$40.00****TOTAL FEES ENCLOSED =****\$880.00**

Amount to be: refunded	\$
charged	\$

☒ **Form PTO-2038**A check in the amount of **\$880.00**

to cover the above fees is enclosed.

☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \_\_\_\_\_ to cover the above fees.

A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **08-1391** A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

**Norman P. Soloway**  
**Hayes, Soloway, Hennessey, Grossman & Haeg, P.C.**  
**175 Canal Street**  
**Manchester, NH 03101**

**Tele # (603) 668-1400**  
**Fax # (603) 668-8567**

(clm)

SIGNATURE

**Norman P. Soloway**

NAME

**24, 315**

REGISTRATION NUMBER

**November 16, 2000**

DATE

**CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)**

Applicant(s): TAPER et al

Docket No.

TIENSE RAFF.28

Serial No.

Filing Date

NOVEMBER 16, 2000

Examiner

Group Art Unit

09/700573

Invention:

**SYNERGISTIC COMPOSITION FOR USE IN THE TREATMENT OF CANCER**I hereby certify that this National Stage Application*(Identify type of correspondence)*

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231

on November 16, 2000  
*(Date)*

Carol McClelland*(Typed or Printed Name of Person Mailing Correspondence)*Carol McClelland*(Signature of Person Mailing Correspondence)*EL570815788US*("Express Mail" Mailing Label Number)***Note: Each paper must have its own certificate of mailing.**

529 Rec'd PCT/PTC 16 NOV2000

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appln. Of: TAPER et al

Filed: NOVEMBER 16, 2000

For: SYNERGISTIC COMPOSITION FOR USE IN THE TREATMENT OF CANCER

DOCKET: TIENSE RAFF.28

BOX PCT

Assistant Commissioner for Patents

Washington, D.C. 20231

PRELIMINARY AMENDMENT

Dear Sir:

Please enter the following amendment prior to examination of this application.

IN THE CLAIMS:

Please cancel claims 1 - 20, without prejudice, and insert new claims 21-40 as follows:

--21. Pharmaceutical composition characterized in that it comprises a combination of an effective dose of inulin and of an anti-metabolic anti-cancer drug.

22. Pharmaceutical composition according to claim 1 wherein the inulin is inulin with a DP up to about 100, or oligofructose or a mixture thereof.

23. Pharmaceutical composition according to claim 1 wherein the inulin is chicory inulin with a (DP) ranging from about 10 to about 30, or oligofructose with a DP ranging from 2 to 7 and containing about 5 wt% in total of glucose, fructose and sucrose.

24. Pharmaceutical composition according to claim 1 wherein the anti-cancer drug is selected from the group consisting of methotrexate, cytarabin, fluorouracil, mercaptopurin, thioguanin, azathioprin and hydroxycarbamide.

25. Pharmaceutical composition according to claim 24 wherein the anti-cancer drug is 5-fluorouracil or methotrexate.

26. Pharmaceutical composition according to claim 1 which additionally to the said anti-metabolic anti-cancer drug contains one or more anti-cancer drugs belonging to the class of anti-metabolic anti-cancer drugs and/or to another class of anti-cancer drugs.

27. Pharmaceutical composition according to claim 1 in which the inulin and the anti-metabolic anti-cancer drug which constitute the combination are simultaneously present in the same galenic formulation.

28. Pharmaceutical composition according to claim 1 in which the inulin and the anti-metabolic anti-cancer drug which constitute the combination are present in separate formulations which together form the pharmaceutical composition.

29. Pharmaceutical composition according to claim 1 wherein the single galenic formulation or the separate galenic formulations forming the pharmaceutical composition are suitable for oral, parenteral or rectal administration, or for tube feeding.

30. Pharmaceutical composition according to claim 28 in which the inulin is present in a functional food or feed.

31. Pharmaceutical composition according to claim 28 in which the anti-cancer drug is present in a formulation which is suitable for oral or parenteral administration.

32. Pharmaceutical composition according to claim 1 for use as a medicament for the treatment of cancer in human.

33. Pharmaceutical composition according to claim 1 for use as a medicament for the treatment of cancer in non-ruminating mammals.

34. Use of a combination of inulin and an anti-metabolic anti-cancer drug for the manufacture of a pharmaceutical composition as defined in claim 1 for the treatment of cancer in humans or in a non-ruminating mammal.

35. Method for the treatment of cancer in a human or in a non-ruminating mammal comprising administering to said being in need of such treatment an effective amount of a pharmaceutical composition as defined in claim 1.

36. Method according to claim 35 wherein the inulin and the anti-metabolic anti-cancer drug of the combination forming the pharmaceutical composition are present in the same galenic formulation constituting the pharmaceutical composition.

37. Method according to claim 35 wherein the inulin and the anti-metabolic anti-cancer drug of the combination forming the pharmaceutical composition are present in separate galenic formulations constituting together the pharmaceutical composition.

38. Method according to claim 37 wherein the separate galenic formulations are administered simultaneously or non-simultaneously.

39. Method according to claim 37 wherein the separate galenic formulations are administered via different methods of administration and the inulin is administered by a method selected from the group consisting of oral, parenteral or rectal administration and administration via tube feeding.


40. Method according to claim 39 wherein the separate galenic formulation containing the inulin is a functional food or feed.--

**REMARKS**

Claims 1-20 have been cancelled in favor of new claims 21-40. The claims have been revised to eliminate multiple dependencies and to place the claims in proper form for filing in the USPTO. No new matter is believed entered by any of the foregoing amendments.

The filing fees have been calculated based on the claims as amended. In the event there are any fee deficiencies or additional fees are payable, please charge them (or credit any overpayment) to our Deposit Account No. 08-1391.

Respectfully submitted,



Norman P. Soloway  
Attorney for Applicant  
Reg. No. 24,315

**CERTIFICATE OF EXPRESS MAILING**

"Express Mail" Mailing Label No. EL570815788US

Date of Deposit NOVEMBER 16, 2000

I hereby certify that this paper and the papers listed thereon are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: BOX PCT, Assistant Commissioner for Patents, Washington, DC 20231.

Signature of Person Mailing Carol McClelland

Name of Person Mailing Carol McClelland  
cb

SYNERGISTIC COMPOSITION FOR USE IN THE TREATMENT OF  
CANCER

5     Field of the invention

This invention relates to a pharmaceutical composition comprising a combination of a non-digestible carbohydrate and an anti-cancer drug , and to its use in the treatment of cancer in humans and in non-ruminating mammals.

10

Background and prior art

For various reasons, cancer has become one of the major causes of death of humans mainly in highly developed and highly industrialised countries.

15

Several kinds of cancer have already been identified. Although not all mechanisms of the carcino-genesis and development of all kinds of cancer have been elucidated so far, cancer is a disease which is known to proceed in several steps, conventionally including the stages of initiation, promotion and progression (Pitot, 1986). The initiation stage is characterised by a neoplastic modification of the genome in normal cells. In the promotion stage, the initiated cells with altered genome express their altered genome by a phenotypically detectable proliferation ( premalignant foci, nodules or benign neoplasms). In the stage of progression, the benign neoplastic cells are transformed into malignant tumor cells proliferating in an uncontrolled manner, locally invading adjacent normal body tissues and organs and finally spreading into distant body tissues and organs by the metastases. The invasion of normal body structures usually results in their malfunctioning and destruction, which eventually results in the death of the affected human.

20

25

30

Cancer is also often seen in mammals in which the disease generally occurs through a mechanism similar to the one in humans.

On the one hand, various methods for the treatment of cancer have already been developed including treatment by surgery, by irradiation (X-rays, gamma rays, isotopes), by chemotherapy or, frequently, by combinations thereof.

35

The method of treatment of humans is commonly chosen taking into account *inter alia* the age and physical condition of the affected human and the kind, the location and the stage of development of the cancer. In a few



cases, the treatment will be effective and able to completely cure the affected person. In most cases, however, the treatment can only delay the carcinogenesis or more or less inhibit the development of the cancer disease and, in spite of bringing some temporary relief to the patient, the final outcome is unfortunately still fatal.

The treatment methods are continuously improving as a result of major research efforts. Invasive techniques, including surgery and irradiation, become more and more efficient as a result of technological developments, but require always more highly sophisticated equipment, making the techniques very costly and less suitable for large scale application. In the search to overcome the drawbacks of invasive treatments as well as for various other reasons, chemotherapy, in combination or not with other treatment methods, has become a major way of attack against cancer during the last two decades. A considerable advantage of anti-cancer drugs resides in the fact that they are easy to administer and current developments enable, in a steadily improving manner, target delivery of the drugs.

The anti-cancer drugs which have been developed are generally classified in one of the following groups:

1. alkylating agents, including e.g. cyclophosphamide (Endoxan®);
2. anti-metabolic drugs, including e.g. 5-fluorouracil and methotrexate;
3. anti-mitotic antibiotics, including e.g. doxorubicine and adriamycin;
4. alcaloidal anti-tumor agents, e.g. vincristine sulphate (Oncovin®);
5. hormones and antihormones,
6. interferons, e.g. alfa-2 b interferon; and
6. various anti-tumor agents,

as disclosed for example in the Répertoire commenté des médicaments, Ed. Centre Belge d'information pharmacothérapeutique, (1987), p. 341-345.

However, most of the anti-cancer drugs have serious disadvantages and drawbacks too. They may present a high degree of toxicity for cells of normal body structures causing, for example, liver and kidney damages. They may also cause an increased sensitivity to opportunistic infections. Often they also provoke various types of discomfort for the treated person, such as, local necrosis of the body structure in which the drug is parenterally administered, and, when the drug is administered orally or via tube feeding, nausea, vomiting, irritation of the mucoses of the digestive tract and diarrhoea. In addition to discomfort commonly caused by anti-cancer drugs, anti-metabolic anti-cancer drugs are known to be fairly toxic and to provoke

additional discomfort, including megaloblastose, and lesions to the liver or the digestive tract such as stomatitis and buccal and gastro-intestinal ulcers.

The disadvantages and drawbacks may considerably limit the use of available anti-cancer drugs. Indeed, often a curative effective dose of the drug can not be given to a patient due to the too high toxicity of the drug to normal cells or to the too high degree of discomfort caused to the patient by the drug.

On the other hand, beneficially inhibitory effects of certain dietary components on the incidence and growth of cancer have been disclosed *inter alia* by Williams and Dickerson (1990); Roberfroid (1991) and Milner (1994). Said components, termed functional food components (Roberfroid, 1995), may have almost no nutritional and/or caloric value but interact with physiological functions in the body in a manner to improve them or to restore them more or less in case of a disfunction.

Amongst the many dietary components, non-digestible carbohydrates, commonly termed dietary fibres, have been found to present preventive effects on carcinogenesis (Nossal, 1993; Perdigon et al., 1993) and possibly inhibitory effects on the promotion of carcinogenesis (Wattenberg, 1992).

Moreover, the relation between the intake of dietary fibres and the reduction of the risk of colon cancer has been disclosed in several publications, e.g. Potter et al., (1996); Howe et al., (1992) and Reddy et al., (1992).

Dietary fibres are commonly defined as components of plant cells which are resistant to hydrolysis by the alimentary enzymes of humans and non ruminating mammals. Dietary fibres comprise cellulose, hemicellulose, pectin, gums, waxes, lignin and certain other non-digestible carbohydrates.

Fructans are carbohydrates which are commonly classified in levans and inulins.

Levans are D-fructans generally consisting of water soluble chains of fructose units which are mostly connected to each other by  $\beta(2-6)$  fructosyl-fructose linkages. Levans originate from the activity of certain bacteria and can be produced by known fermentation techniques as well as by enzymatic synthesis. Levans usually occur as a polydisperse mixture of polyfructose chains. These chains may be linear, but in general they are branched.

As  $\beta(2-6)$  fructosyl-fructose linkages are not hydrolysed by alimentary enzymes in the upper part of the digestive tract of humans and non

ruminating mammals, levans pass almost unaltered into the colon where they are fermented by intestinal bacteria.

Inulins are D-fructans consisting of water soluble chains of fructose units too, but they are composed of chains in which the fructose units are connected to each other mostly or exclusively by  $\beta(2-1)$  fructosyl-fructose linkages. Besides, inulin-type polyfructose chains often end in a glucose unit. Inulin mostly occurs as a polydisperse mixture of linear polyfructose molecules, as for example inulin from chicory, but inulin can also occur as a polydisperse mixture of branched polyfructose molecules, as for example inulin from dahlia and inulin from agave.

Inulins can be represented by the general formulae  $GF_n$  and  $F_n$  wherein G represents a glucosyl unit, F represents a fructosyl unit, and n represents the number of fructosyl units linked to each other in the carbohydrate chain. The number of saccharide units (fructose and glucose units) in one inulin molecule, *i.e.* the values  $n+1$  in formula  $GF_n$  and n in formula  $F_n$ , are referred to as the degree of polymerisation, represented by (DP). Often the parameter average degree of polymerisation of the inulin, represented by  $(\overline{DP})$ , is used too, which is the value corresponding to the total number of saccharide units divided by the total number of inulin molecules present in a given composition, without taking into account possibly present mono- and disaccharides (De Leenheer, 1996).

Inulins are synthesised by many plant species, in parts of which they may be stored as reserve carbohydrates, but inulins can also originate from bacterial activity and can be enzymatically synthesised as well. Inulin from plant origin is a polydisperse composition of polyfructose chains with a degree of polymerisation (DP) ranging from 3 to about 100, whereas inulin from bacterial origin usually has a higher (DP). The inulin profile, *i.e.* the distribution profile of the inulin chains according to their (DP), which to a certain extent is indicated by the average degree of polymerisation  $(\overline{DP})$ , depends from various factors, including the plant species, the time in the plant life cycle when the plant part is harvested, and the way the plant part is processed into inulin.

In roots of chicory, in tubers of dahlia and Jerusalem artichoke, and in the pinia of agave, inulin can occur at concentrations of about 10% to about 20 % on fresh weight. Inulin can be extracted easily from these plant parts, for example by extraction of the shredded plant parts with warm water. Then the crude inulin is purified and optionally fractionated to remove undesired fractions of carbohydrates. Finally, the inulin is isolated in

particulate form, usually by spray drying or by directed crystallisation. These different process steps are well known in the art. At industrial scale, inulin is mainly obtained from roots of chicory.

5 Inulin from chicory is commercially available in various grades, for example as RAFTILINE® from ORAFTI, (Tienen, Belgium). Typical RAFTILINE® grades are, for example, ST (which has a ( $\overline{DP}$ ) of about 10 and contains in total about 8 % by weight glucose, fructose and sucrose), LS (which also has a ( $\overline{DP}$ ) of about 10 but which contains in total less than 1 % by weight glucose, fructose and sucrose), and HP (which has a ( $\overline{DP}$ )  $\geq 23$ ,  
10 commonly a ( $\overline{DP}$ ) of about 25 to about 30, and is essentially free of glucose, fructose and sucrose).

Inulin-type molecules of general formulae  $GF_n$  and  $F_n$  having a lower degree of polymerisation (DP), usually defined as a (DP) < 10, are often interchangeably termed oligofructoses, inulo-oligosaccharides and fructo-  
15 oligosaccharides, represented by FOS.

Unless specified otherwise, the term inulin herein is meant to comprise both inulin and oligofructose.

Oligofructose, which is thus an inulin of which the composing polyfructose chains have a (DP) < 10, is usually obtained by partial, acidic or  
20 enzymatic hydrolysis of inulin, but can also be obtained by enzymatic synthesis from sucrose, according to techniques well-known in the art.

Several grades of oligofructose are commercially available, for example from ORAFTI (Tienen, Belgium) under the brand name RAFTILOSE®, for example, RAFTILOSE® P95 which contains about 95 % by weight  
25 oligofructose with a degree of polymerisation (DP) ranging from 2 to 7 and contains about 5 % by weight in total of glucose, fructose and sucrose.

Due to the presence of  $\beta(2-1)$  fructosyl-fructose linkages between the fructosyl units of the inulin-type polyfructose chains, inulin is not digested by alimentary enzymes in the upper part of the digestive tract of  
30 humans and non ruminating mammals, but passes essentially unaltered into the lower part of the digestive tract to reach the colon where it is fermented by intestinal bacteria, while selectively promoting the growth of certain beneficial bacteria, particularly *Bifidobacteria* (Gibson et al., 1995). This bifidogenic effect, also called prebiotic effect, is known to exert beneficial  
35 effects on various physiological functions in the body.

In view of their almost non-digestibility by alimentary enzymes of humans and non ruminating mammals, fructans, levan-type fructans as

well as inulin-type fructans, are generally considered as soluble dietary fibres.

EP 0 879 600,  
In patent application ~~EP 97870069.8~~, the use has been described of fructan-type carbohydrates, particularly chicory inulin, with an average degree of polymerisation ( $\overline{DP}$ ) of at least 15, for the manufacture of a composition for the prevention and treatment of colon cancer in non-bovine mammals, particularly in humans. Optionally, said composition can also comprise a physiologically active substance, a drug or pro-drug, but no particulars have been disclosed in this respect.

Furthermore, intraperitoneal injection of gamma-inulin, a specific polymorphic form of dahlia inulin, has been demonstrated to prolong the survival time of melanoma bearing mice (Cooper, 1986).

More recent studies revealed that non-digestible carbohydrates, including oligofructose and inulin, present inhibitory effects on the growth of intramuscularly transplanted mouse tumors (Taper et al., 1997).

Patent application EP 0 692 252 A1, discloses a composition containing inulin or oligofructose which presents a preventive effect on carcinogenesis and an inhibitory effect on the growth of cancer in mammals, particularly mammary cancer. EP 0 692 252 A1 also discloses compositions which in addition to inulin or oligofructose comprise conventional chemotherapeutic products actively destroying malignant tumor cells. In this way, the combination of the physiologically beneficial effects of non-digestible carbohydrates and of the curative effects of anti-cancer drugs are sought. Furthermore, in Example 7 (page 12 of EP 0 692 252 A1) is mentioned that to determine potential synergistic therapeutic effects, a pharmaceutical composition comprising RAFTILINE® (i.e. chicory inulin) and a conventional chemotherapeutic product actively destroying malignant tumor cells, is prepared and a test is described wherein doxorubicine (an anti-cancer drug of the class of the antimitotic antibiotics) was injected to mice fed oligofructose/RAFTILINE® which were previously inoculated with L1210 leukaemic tumor cells. However, EP 0 692 252 A1 is completely silent about the outcome of the test and about possible synergistic effects between a non-digestible fructan-type carbohydrate and conventional anti-cancer drugs.

The combined effect of levan and four cytotoxic agents on the growth of experimental tumors in mice has been published (Leibovici et al., 1983). Additive effects were observed with all the combinations of levan and the cytotoxic agents, except for the combination of levan and methotrexate, an

anti-metabolite anti-cancer agent, which gave a synergistic effect on Lewis lung carcinoma. However, no synergistic effect was observed for the combination of levan and 5-fluorouracil, an other anti-metabolite anti-cancer drug.

5

### The problem

In view of the tremendous social and economical impact of cancer on individuals as well as on society in general, huge efforts are continuously made world-wide to find new or improved products, compositions and methods for the treatment of cancer. In particular, the search is continued in order to find highly effective drugs, preferably with a low degree of toxicity to normal cells, and compositions thereof, which are providing good therapeutic effects while provoking minimal discomfort to the patient.

### Description of the invention

The present invention provides a solution to one or more of the problems mentioned above, by providing (i) a novel pharmaceutical composition comprising a synergistic combination of a non-digestible carbohydrate, i.e. an inulin (including inulin, oligofructose and mixtures thereof) and an anti-cancer drug, (ii) said composition for use in the treatment of cancer in humans and in non-ruminating mammals, (iii) the use of said combination for the manufacture of a medicament for the treatment of cancer in humans and in non-ruminating mammals, and (iv) the use of said composition in a method for treatment of cancer in humans and in non-ruminating mammals.

By the term cancer is meant herein any kind of cancer occurring in humans and in non-ruminating mammals, irrespective of the stage of development of said cancer, thus including, in particular, the initiation, promotion, progression stages and the metastasis stage.

The invention is based on the findings made by the inventors that the combination of inulin and an anti-metabolic anti-cancer drug, not only results in an additive therapeutical effect vis-à-vis the carcinogenesis and the growth of cancer in humans and in non-ruminating mammals, but surprisingly provokes a synergistic therapeutical effect vis-à-vis said disease.

So, in one aspect the present invention relates to a novel pharmaceutical composition comprising a synergistic combination of inulin and an anti-metabolic anti-cancer drug, which combination provokes a

synergistic therapeutical effect on the carcinogenesis and growth of cancer in humans and in non-ruminating mammals.

Typically suitable inulins include chicory inulin, in particular, inulin with a ( $\overline{DP}$ ) of about 10, such as for example RAFTILINE® ST and  
5 RAFTILINE® LS, and inulin with a ( $\overline{DP}$ )  $\geq 23$ , such as, for example, RAFTILINE® HP and a suitable oligofructose is, for example, RAFTILOSE® P95, all from ORAFTI (Belgium).

The term therapeutical effect used herein refers to an inhibitory effect on the incidence and growth of cancer as well as to a curative effect  
10 provoking the decrease of the volume of an existing cancer and possibly the regression or curing of the cancer disease.

By anti-metabolic anti-cancer drug is meant a drug selected from said class of anti-cancer drugs which embraces products which compete with the normal metabolites of nucleic acids in cell synthesis and in cell growth  
15 pathways. This class of drugs is comprising methotrexate, cytarabin, fluorouracil, mercaptopurin, thioguanine, azathioprin and hydroxy-carbamide.

It is understood that the term drug used herein includes the drug *per se* as well as a pro-drug, i.e. a compound which in the body is transformed into  
20 the corresponding drug.

The composition according to the invention is suitable in the first place for the treatment of cancer in humans. However, it is very suitable too for the treatment of cancer in non-ruminant mammals, such as for example horses, rabbits, dogs and cats.

In a preferred embodiment the inulin is a chicory inulin with a ( $\overline{DP}$ ) of about 10. In another preferred embodiment the inulin is a chicory inulin with a ( $\overline{DP}$ ) of  $\geq 23$ , typically of about 25 to about 30. In still another preferred embodiment, the inulin is an oligofructose, more preferably an oligofructose with a ( $\overline{DP}$ ) of 2 to 7.

In a further preferred embodiment, the anti-metabolic drug is  
30 5-fluorouracil or methotrexate.

In a particularly preferred embodiment the inulin is chicory inulin or oligofructose or a mixture thereof and the anti-cancer drug is 5-fluorouracil or methotrexate.

Furthermore, a composition according to the present invention may  
35 comprise, instead of one anti-metabolic drug, a mixture of two or more anti-metabolic drugs as well as a mixture of one or more anti-metabolic drugs with one or more anti-cancer drugs belonging to a different class.

The composition according to the invention can be prepared by conventional methods, comprising, for example, mixing the desired amounts of the active components, optionally in combination with one or more pharmaceutically acceptable solvents, diluents, excipients, and/or additives commonly used in galenic pharmacy.

The compositions can be presented in conventional, well known galenic forms for oral, parenteral or rectal administration, or for tube feeding. The compositions for oral administration can for example be liquids, gels or solids and exist, for example, as tablets, coated tablets, coated pills, capsules, granules, solutions, syrups, suspensions or emulsions. The compositions for administration via tube feeding can for example be solutions, syrups, suspensions or emulsions which optionally can be mixed with normal food compositions for tube feeding. The compositions for rectal administration may for example be solids, gels or liquids, presented for example in the form of suppositories, gels, solutions, suspensions or emulsions. The composition for parenteral administration can for example be in the form of a solution, emulsion or suspension, suitable for said administration, including for subcutaneous, intramuscular, intravenous and intraperitoneal administration.

Suitable galenic forms also include retard release forms as well as sustained release forms which are well known in the art.

The composition according to the invention comprises at least an ~~active~~<sup>effective</sup> dose of the inulin as well as of the anti-cancer drug or drug mixture. A dose which is effective for treatment of cancer can be formulated in the form of a single dose unit or of several partial dose units, the administration of which can be spread over a certain period of time. Usually the composition according to the invention will be administered spread over several partial dose units, and spread, possibly with certain intervals, over one or more days or weeks.

The effective dose of the synergistic combination of inulin and anti-metabolic anti-cancer drug may depend on various factors, including the affected being, a human or species of non-ruminating mammals, its age and physical condition, the kind and stage of development of the cancer, the kind of inulin and of anti-cancer drug, and the method of administration of the synergistic combination. The effective dose, the optimal galenic form and unit dose, and the way of administration can be determined by the skilled person following conventional methods.



5 A particularly interesting feature of the compositions according to the invention resides in the fact that the active ingredients of the synergistic combination, i.e. the inulin and the anti-metabolic anti-cancer drug, can be administered to the human or non ruminating mammal (i) simultaneously and present in the same galenical formulation (constituting the pharmaceutical composition according to the present invention) , or (ii) simultaneously but present in two separate galenic formulations (constituting together the pharmaceutical composition according to the present invention) and optionally via two different methods of administration, as well as (iii) separately, i.e. non simultaneously, via two separate galenic formulations (constituting together the pharmaceutical composition according to the present invention) and optionally via two different methods of administration.

15 It is understood that in the above mentioned methods of administration, the inulin component as well as the anti-cancer drug of the composition of the invention, can be administered orally, via tube feeding, parenterally or rectally.

20 Furthermore, the combined composition or each of the active components can be administered locally or systemically, and they, accordingly, have to be present in a galenic formulation which is suitable for the method of administration.

25 When the fructan component and the anti-cancer drug component of the combination according to the invention are not simultaneously administered to the human or mammal, it is of course compulsory that they are brought into the body of said being in such a manner that their functional effects on the human or mammal are simultaneously present in order to provoke the synergistic effect in accordance with the present invention.

30 According to one preferred embodiment, both active ingredients are administered simultaneously in one pharmaceutical composition to the human or mammal.

In an other preferred embodiment, both active ingredients are administered simultaneously but in separate formulations. Optionally a different way of administration for each of the formulations can be used.

35 In a further preferred embodiment both active ingredients are administered separately in separate formulations and optionally via different methods of administration and/or at different time periods.

If the active ingredients are not administered simultaneously via the same formulation, the anti-cancer drug is preferably administered orally or parenterally, whereas the inulin is preferably administered orally, via tube feeding or parenterally. The inulin can be administered in various galenic formulations, such as for example tablets, capsules, syrups, solutions, suspensions or emulsions. The inulin can even be administered orally in the form of a functional food or feed, i.e. a food or feed product which during its manufacture has been provided with the desired amount of inulin, such as, for example, dairy products e.g. yoghurts or cheeses; jams or marmalades; baked goods e.g. biscuits, breads or breakfast cereals; desserts e.g. puddings or ice-creams; table spreads, e.g. margarines; drinks; meal replacers; or confectionery, e.g. gums.

In a further preferred embodiment, inulin is already administered to the human or mammal some time, for example one week, before the composition of the invention is administered. Without wishing to be bound by any theory, it is supposed that as a result of the bifidogenic effect of the previously administered inulin, the intestinal flora and/or the effected functions have been brought into a condition in which the synergistic effect provoked by the combination of active ingredients according to the invention can develop optimally.

In a further aspect the invention relates to a pharmaceutical composition as defined herein above for the treatment of cancer in humans or in non-ruminating mammals.

In still a further aspect, the invention relates to the use of a combination of inulin and an anti-metabolic anti-cancer drug for the manufacture of a pharmaceutical composition as defined herein above for the treatment of cancer in humans or in non-ruminating mammals.

In still another aspect, the invention relates to a method for the treatment of cancer in humans or in non-ruminating mammals, comprising administering to said being in need for such treatment an effective dose of the pharmaceutical composition comprising a synergistic combination of inulin and an anti-metabolic anti-cancer drug as defined above, said active ingredients, i.e. the inulin and the anti-cancer drug, being administered either simultaneously in the same or in separate formulations, or non-simultaneously in separate formulations and optionally after previous administration of inulin during a certain period, as described herein before.

### Examples

In support of the present invention, the following illustrative data are given regarding experiments wherein the therapeutical effects on cancer in mice of a composition according to the present invention are compared with the therapeutical effects of a composition containing a combination of inulin with an anti-cancer drug which belongs to a different class.

To investigate whether dietary treatment with inulin ( inulin or oligofructose [FOS] ) would be able to potentiate the therapeutic effects of anti-cancer drugs commonly utilised in human cancer treatment, representatives of 4 principal classes of anti-cancer drugs have been chosen and compared in the following test.

The drugs were: endoxan (belonging to the class of alkylating agents), adriblastina (adriamycin) ( belonging to the class of antimitotic antibiotics), 5-fluorouracil (belonging to the class of anti-metabolic agents) and oncovin (belonging to the class of antineoplastic alkaloids).

Viable, neoplastic cells ( $10^6$ ) from the ascitic form of a transplantable mouse liver tumor (TLT) (Taper, 1966 and Cappucino, 1966) were intraperitoneally transplanted into 12 per group young adult NMRI male mice weighing about 30 g, supplied by "Animalerie Facultaire", UCL, Brussels. Mice of the experimental groups were fed with a basal diet supplemented with 15 % FOS or inulin starting 7 days before tumor transplantation up to the end of the experiment. Control animals received the basal diet for experimental animals AO4 furnished by UAR, Villemoisson sur Orge, France, and water ad libitum.

A single, subtherapeutic dose of cytotoxic drugs was intraperitoneally injected 48 hours after intraperitoneal TLT tumor transplantation at following doses: endoxan 80 mg/kg; adriamycin 0.1 mg/kg; oncovin 0.5 mg/kg and 5-fluorouracil 40 mg/kg.

The criteria for the evaluation of results were the mortality rates expressed by mean survival time (MST) and the percentage of increase of life span (ILS) in experimental groups compared with the controls, calculated according to the NCI instructions (Geron et al., 1972). The results of each experiment were confirmed by another experiment performed at another time and were cumulatively calculated (as presented in Table 1).

The results concerning the survival rates of mice bearing the ascitic form of a TLT tumor, observed in 2 separately performed experiments on each type of anti-cancer drug (12 mice per group), are cumulatively presented in Table 1 below.

In all the experiments a chemotherapy potentiating effect has been observed for dietary FOS or inulin. Obviously this therapeutic effect was somewhat different for the various drugs. Only for 5-fluorouracil treatment a synergistic therapeutic effect has been observed. For treatment with oncovin, endoxan and adriamycin, the therapeutic effects had only additive character. There is no significant difference observed between treatment with inulin or FOS.

All results of supplementary dietary FOS treatment were statistically very highly significant ( $p < 0.001$ ). There were no negative results in any of the separately performed experiments. Furthermore, no gastro-intestinal troubles were observed in all animals after the direct introduction of 15 % FOS or inulin in the diet. There was no sign of increased drug toxicity after dietary introduction of both inulin or FOS (e.g. there was no difference in body weights between mice treated only with a cytotoxic drug and those treated with supplementary inulin or FOS).

Furthermore, it should be noted that in the experiments unfavourably therapeutic conditions were deliberately utilised by the administration of a single, sub-therapeutic dose of cytotoxic drug 48 hours after the intra-peritoneal transplantation of a very aggressive and rapidly growing ascitic form of mouse tumor.

In a further experiment, carried out in a similar manner as the previous experiment, the effects were examined of a composition according to the invention, containing a combination of the anti-metabolite anti-cancer drug methotrexate and inulin or FOS, in comparison with the effects of the single components.

The effects were evaluated via the survival criteria of N.M.RI mice bearing ascitic TLT tumors, treated with a single i.p. dose of 20 mg/kg methotrexate (10 investigated mice in each group) and the results are presented in Table 2 below.

TABLE 1.

Therapeutic effects of FOS or inulin associated to a single dose of different cytotoxic drugs administered to ascitic TLT tumor bearing mice

5

Treatment	ILS (%)	Effect of combined treatment	Statistical significance
5-Fluorouracil *	18.75		
FOS *	12.5		
5-Fluorouracil + FOS	40.6	Synergistic	p < 0.001
Adriamycin *	14.7		
FOS *	5.9		
Adriamycin + FOS *	17.6	Additive	p < 0.001
Endoxan *	0		
FOS *	25.0		
Endoxan + FOS *	25.0	Additive	p < 0.001
Oncovin *	33.33		
FOS *	13.33		
Inulin *	10.0		
Oncovin + FOS *	46.66	Additive	p < 0.001
Oncovin + Inulin *	43.33	Additive	p < 0.01

10

Each of the differently treated group of 12 mice had its individual, untreated, control group to which it was compared in the calculation of the increase of life span (ILS). The cumulatively presented results are based each on 2 experiments independently performed at different time. Lagrank test was utilised for statistical analysis of the results.

\*: comparative test

15

TABLE 2.

Therapeutic effects of FOS or inulin associated to a single dose of  
methotrexate administered i.p. at 20 mg/kg to ascitic TLT tumor bearing  
mice

Treatment	ILS (%)	Effect of combined treatment
untreated (control) *		
methotrexate *	2	
FOS *	5	
inulin *	11	
methotrexate + FOS	29	Synergistic
methotrexate + inulin	20.5	Synergistic

\*: comparative test

From the comparative data presented in Tables 1 and 2, it clearly follows that the composition according to the present invention comprising a combination of inulin and an anti-metabolic anti-cancer drug has a synergistic therapeutical effect on cancer in mice, whereas for the compositions containing inulin and an anti-cancer drug of an other class only an additive effect is observed. Besides, the compositions of the invention provoked no disadvantageous effects on the digestive tract and were not potentiating the toxicity of the anti-cancer drug.

As a result of said synergistic effect the compositions of the invention present considerable advantages over conventional anti-cancer compositions. For example, compared to a conventional composition containing the same concentration of anti-cancer drug, the therapeutical effect of a composition of the invention is significantly increased which may lead to a considerable improvement of the bodily condition of the treated human or mammal and which may enable to better control the disease and even enable to have restored to a more or lesser extent the normal physiological functions and affected body structures. On the other hand, said synergistic effect can enable the use of certain anti-cancer drugs, which are fairly toxic or provoke disadvantageous side effects, in compositions according to the invention in reduced concentrations while still maintaining the same or a desirable level of therapeutical effect. Said synergistic effect makes it even possible to use certain anti-cancer drugs which, at the concentration they have to be used in conventional composition to obtain a desired therapeutical effect, are too toxic or provoke such undesirable side effects that they can not be supported by the treated human or mammal.

In addition, the treated human or mammal also enjoys the known beneficial effects resulting from the bifidogenic effect of the inulin which is present in the composition of the invention.

Consequently, it can be concluded that the composition and method according to the invention present a considerable improvement in the fight against cancer in humans and in non-ruminating mammals.

REFERENCES

- Williams, C.M., Dickerson, J.W., Nutr. Res. Rev., 3, 45-100, (1990)
- Roberfroid, M.B., Mutation Res., 259, 351-362, (1991)
- 5 Milner, J.A., Functional Foods, pp. 39-70, Chapman and Hall, New York, London (1994)
- Roberfroid, M.B., World of ingredients, 3, 42-44 (1995)
- Nossal, G.J.V., Sci. Amer., 269, 21-30 (1993)
- Perdigon, G. et al., Int. J. Immunother., 9, 29-52 (1993)
- 10 Wattenberg, L., Cancer; Res., 52, 2085s-2091s, (1992)
- Potter, J. et al., Principles of Chemoprevention, IARC Scientific Publication N° 139, 61-90, (1996);
- Howe, G.R. et al., J. Natl. Cancer Inst., 84, 1887-1896, (1992);
- Reddy, B.S. et al., Gastroenterol., 102, 1475-1482, (1992).
- 15 De Leenheer, L., Carbohydrates as Organic Raw Materials, Vol. III, p.67-92, (1996)
- Gibson, G.R. et al., Gastroenterology, 108, 975-982, (1995) and J. Nutr., 125, 1401-1412, (1995)
- Cooper, P.D. et al., Mol.Immunol., 23, 903-908, (1986)
- 20 Taper, H.S. et al., Int. J. Cancer, 71, 1109-1112 (1997).
- Taper, H.S. et al., Cancer Res., 26, 193-198, (1966)
- Cappucino, J.G. et al., Cancer Res., 26, 689-694, (1966)
- Geron, R.J. et al., Cancer Chemother. Reports, 3, 1-103, (1972).
- Pitot H.C., Fundamentals of Oncology, pp. 139-200, Marcel Dekker Ed.,
- 25 New York (1986).



Claims*characterised in that it comprises a*

1. Pharmaceutical composition ~~comprising a synergistic combination~~  
<sup>an effective dose of</sup> of inulin and <sup>of</sup> an anti-metabolic anti-cancer drug.

2. Pharmaceutical composition according to claim 1 wherein the  
 5 inulin is inulin with a DP up to about 100, or oligofructose or a mixture thereof.

3. Pharmaceutical composition according to claim 1 or claim 2,  
 wherein the inulin is chicory inulin with a ( $\overline{DP}$ ) ranging from about 10 to  
 10 about 30, or oligofructose with a DP ranging from 2 to 7 and containing about 5 wt% in total of glucose, fructose and sucrose.

4. Pharmaceutical composition according to any one of claims 1 to 3  
 wherein the anti-cancer drug is selected from the group consisting of  
 methotrexate, cytarabin, fluorouracil, mercaptopurin, thioguanin,  
 15 azathioprin and hydroxycarbamide.

5. Pharmaceutical composition according to claim 4 wherein the anti-  
 cancer drug is 5-fluorouracil or methotrexate.

6. Pharmaceutical composition according to any one of claims 1 to 5  
 which additionally to the said anti-metabolic anti-cancer drug contains one  
 or more anti-cancer drugs belonging to the class of anti-metabolic anti-cancer  
 20 drugs and/or to another class of anti-cancer drugs.

7. Pharmaceutical composition according to any one of claims 1 to 6 in  
 which the inulin and the anti-metabolic anti-cancer drug which constitute  
 the ~~synergistic~~ combination are simultaneously present in the same galenic  
 formulation.

8. Pharmaceutical composition according to any one of claims 1 to 6 in  
 which the inulin and the anti-metabolic anti-cancer drug which constitute  
 the ~~synergistic~~ combination are present in separate formulations which  
 together form the pharmaceutical composition.

9. Pharmaceutical composition according to any one of claims 1 to 8  
 30 wherein the single galenic formulation or the separate galenic formulations forming the pharmaceutical composition are suitable for oral, parenteral or rectal administration, or for tube feeding.

10. Pharmaceutical composition according to claim 8 in which the  
 inulin is present in a functional food or feed.

35 11. Pharmaceutical composition according to claim 8 in which the anti-cancer drug is present in a formulation which is suitable for oral or parenteral administration.

12. Pharmaceutical composition according to any one of claims 1 to 11 for use as a medicament for the treatment of cancer in humans.

13. Pharmaceutical composition according to any one of claims 1 to 11 for use as a medicament for the treatment of cancer in non-ruminating mammals.

14. Use of a combination of inulin and an anti-metabolic anti-cancer drug for the manufacture of a pharmaceutical composition as defined in any one of claims 1 to 11 for the treatment of cancer in humans or in a non-ruminating mammal.

15. Method for the treatment of cancer in a human or in a non-ruminating mammal comprising administering to said being in need of such treatment an effective amount of a pharmaceutical composition as defined in any one of claims 1 to 11.

16. Method according to claim 15 wherein the inulin and the anti-metabolic anti-cancer drug of the synergistic combination forming the pharmaceutical composition are present in the same galenic formulation constituting the pharmaceutical composition.

17. Method according to claim 15 wherein the inulin and the anti-metabolic anti-cancer drug of the synergistic combination forming the pharmaceutical composition are present in separate galenic formulations constituting together the pharmaceutical composition.

18. Method according to claim 17 wherein the separate galenic formulations are administered simultaneously or non-simultaneously.

19. Method according to claim 17 wherein the separate galenic formulations are administered via different methods of administration and the inulin is administered by a method selected from the group consisting of oral, parenteral or rectal administration and administration via tube feeding.

20. Method according to claim 19 wherein the separate galenic formulation containing the inulin is a functional food or feed.

## DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

Attorney Docket No: TIENSE RAFF.28  
First Named Inventor: TAPER Henryk  
Complete if known: Serial No: \_\_\_\_\_ Filing Date: November 16, 2000  
Group Art Unit: \_\_\_\_\_ Examiner: \_\_\_\_\_

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled SYNERGISTIC COMPOSITION FOR USE IN THE TREATMENT OF CANCER, the specification of which is attached hereto.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, S. 1.56(a).

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed:

### Prior Foreign Application(s):

<u>Prior Foreign Application(s):</u>			<u>Priority Claimed</u>	<u>Certified Copy Attached</u>
<u>98870113.2</u>	<u>EP</u>	<u>05.18.1998</u>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
(Number)	(Country)	(Month/Day/Year Filed)		
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No
(Number)	(Country)	(Month/Day/Year Filed)		

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below:

Application No: \_\_\_\_\_ Filing Date: \_\_\_\_\_

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

PCT/EP99/0 33 99	05.18.1999	
US Parent Application No. or PCT Parent Appln. No	Parent Filing Date	Parent Patent Number (if applicable)

And I hereby appoint HAYES, SOLOWAY, HENNESSEY, GROSSMAN & HAGE, P.C., a firm composed of:

Oliver W. Hayes, Reg. No. 15,867 Steven J. Grossman, Reg. No. 35,001  
Norman P. Soloway, Reg. No. 24,315 Susan H. Hage, Reg. No. 29,646  
William O. Hennessey, Reg. No. 32,032 Donald J. Perreault, Reg. No. 40,126  
or any of them, of 175 Canal Street, Manchester, New Hampshire 03101 (Telephone: 603-668-1400) and

Edmund P. Pfleger, Reg. No. 41,252 Dale F. Regelman, Reg. No. 45,625  
or any of them, of 130 West Cushing Street, Tucson, Arizona 85701 (Telephone: 520-882-7623)

as my attorneys with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent Office connected therewith.

Please direct all future correspondence in connection with this application to the attention of **Norman P. Soloway** HAYES, SOLOWAY, HENNESSEY, GROSSMAN & HAGE, P.C., 175 Canal Street, Manchester, New Hampshire 03101 (Telephone: 603-668-1400).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: TAPER Henryk


First Inventor's signature [Signature] Date October 12, 2000

Residence: Roeselbergweg, 8 B - 3012 Wilsele BELGIUM BEX

Citizenship: Belgian

Post Office Address: Same as Residence

Full name of second joint inventor: FRIPPIAT Anne


2-00 Second Inventor's signature  Date October 26, 2000

Residence: Abelooslaan, 14 B- 1938 Sterrebeek BELGIUM BEX

Citizenship: Belgian

Post Office Address: Same as Residence

Full name of third joint inventor: VAN LOO Jan


3-00 Third Inventor's signature  Date October 22, 2000

Residence: Lepelstraat, 3 B - 3000 Leuven BELGIUM BEX

Citizenship: Belgian

Post Office Address: Same as Residence

Full name of fourth joint inventor: ROBERFROID Marcel

4-00 Fourth Inventor's signature  Date October 26, 2000

Residence: Rue du Coq, 71 B - 1180 Bruxelles BELGIUM BEX

Citizenship: Belgian

Post Office Address: Same as Residence

Full name of fifth joint inventor: \_\_\_\_\_

Fifth Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Residence: \_\_\_\_\_

Citizenship: \_\_\_\_\_

Post Office Address: Same as Residence

Full name of sixth joint inventor: \_\_\_\_\_

Sixth Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Residence: \_\_\_\_\_

Citizenship: \_\_\_\_\_

Post Office Address: Same as Residence